Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


05.02.2024

1 Ann Surg
3 Ann Surg Oncol
1 Anticancer Res
4 BMC Cancer
2 Br J Cancer
1 Breast Cancer
1 Breast Cancer (Auckl)
4 Breast Cancer Res
7 Breast Cancer Res Treat
2 Cancer Lett
3 Clin Breast Cancer
3 Discov Oncol
1 Int J Cancer
1 J Clin Invest
1 J Clin Oncol
1 J Natl Cancer Inst
1 J Nucl Med
1 Lancet Oncol
1 NPJ Breast Cancer
2 Oncogene
2 PLoS One
2 Radiol Imaging Cancer


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Ann Surg

  1. WU CA, Ho I, Minasian A, Keuroghlian AS, et al
    Variability in Medicaid Coverage for Gender-affirming Surgeries Across U.S. States.
    Ann Surg. 2024;279:542-548.
    PubMed         Abstract available


    Ann Surg Oncol

  2. KLASSEN CL, Viers LD, Ghosh K
    Following the High-Risk Patient: Breast Cancer Risk-Based Screening.
    Ann Surg Oncol. 2024 Feb 1. doi: 10.1245/s10434-024-14957.
    PubMed         Abstract available

  3. CHOI S, Borowsky PA, Morgan O, Kwon D, et al
    A Multi-institutional Analysis of Factors Influencing the Rate of Positive MRI Biopsy Among Women with Early-Stage Breast Cancer.
    Ann Surg Oncol. 2024 Jan 29. doi: 10.1245/s10434-024-14954.
    PubMed         Abstract available

  4. NG TP, Loo BYK, Yong N, Chia CLK, et al
    Review: Implant-Based Breast Reconstruction After Mastectomy for Breast Cancer: A Meta-analysis of Randomized Controlled Trials and Prospective Studies Comparing Use of Acellular Dermal Matrix (ADM) Versus Without ADM.
    Ann Surg Oncol. 2024 Jan 29. doi: 10.1245/s10434-024-14943.
    PubMed         Abstract available


    Anticancer Res

  5. DODDI S, Hibshman T, Salichs O, Tirumani SH, et al
    Disparities in Mortality Trends of Breast Cancer by Racial and Ethnic Status in the United States.
    Anticancer Res. 2024;44:751-755.
    PubMed         Abstract available


    BMC Cancer

  6. WEAVER KE, Dressler EV, Smith S, Nightingale CL, et al
    Cardiovascular health assessment in routine cancer follow-up in community settings: survivor risk awareness and perspectives.
    BMC Cancer. 2024;24:158.
    PubMed         Abstract available

  7. ZHANG Y, Guan Y, Zheng X, Li C, et al
    Hypoxia-induced miR-181a-5p up-regulation reduces epirubicin sensitivity in breast cancer cells through inhibiting EPDR1/TRPC1 to activate PI3K/AKT signaling pathway.
    BMC Cancer. 2024;24:167.
    PubMed         Abstract available

  8. GOLESTAN A, Tahmasebi A, Maghsoodi N, Faraji SN, et al
    Unveiling promising breast cancer biomarkers: an integrative approach combining bioinformatics analysis and experimental verification.
    BMC Cancer. 2024;24:155.
    PubMed         Abstract available

  9. BELAID I, Baya MF, Ben Ayed S, Ben Ayed A, et al
    Transcutaneous canine breast cancer detection in Tunisia: a pilot study.
    BMC Cancer. 2024;24:151.
    PubMed         Abstract available


    Br J Cancer

  10. HOLT S, Verrill M, Pettit L, Rigg A, et al
    A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer.
    Br J Cancer. 2024 Feb 2. doi: 10.1038/s41416-024-02588.
    PubMed         Abstract available

  11. GAILLARD T, Piketty J, Feron JG, Girard N, et al
    Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib.
    Br J Cancer. 2024 Jan 27. doi: 10.1038/s41416-024-02580.
    PubMed         Abstract available


    Breast Cancer

  12. ZHENG H, Wu L, Chen J, Na N, et al
    Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models.
    Breast Cancer. 2024 Jan 30. doi: 10.1007/s12282-024-01543.
    PubMed         Abstract available


    Breast Cancer (Auckl)

  13. CHAI T, Yue W, Xu P, Gildea J, et al
    Caveolin-1, a Determinant of the Fate of MCF-7 Breast Cancer Cells.
    Breast Cancer (Auckl). 2024;18:11782234241226802.
    PubMed         Abstract available


    Breast Cancer Res

  14. SHARMA A, Weitz P, Wang Y, Liu B, et al
    Development and prognostic validation of a three-level NHG-like deep learning-based model for histological grading of breast cancer.
    Breast Cancer Res. 2024;26:17.
    PubMed         Abstract available

  15. HAN X, Guo Y, Ye H, Chen Z, et al
    Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
    Breast Cancer Res. 2024;26:18.
    PubMed         Abstract available

  16. NIE J, Dang S, Zhu R, Lu T, et al
    ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
    Breast Cancer Res. 2024;26:19.
    PubMed         Abstract available

  17. LYNCE F, Stevens LE, Li Z, Brock JE, et al
    TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
    Breast Cancer Res. 2024;26:20.
    PubMed         Abstract available


    Breast Cancer Res Treat

  18. JOHANSSON H, Bellerba F, Macis D, Bertelsen BE, et al
    Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials.
    Breast Cancer Res Treat. 2024 Jan 26. doi: 10.1007/s10549-023-07241.
    PubMed         Abstract available

  19. LEE IH, Lee SJ, Kang B, Lee J, et al
    Exploration of MELK as a downstream of Del-1 and druggable targets in triple-negative breast cancer.
    Breast Cancer Res Treat. 2024 Jan 27. doi: 10.1007/s10549-023-07198.
    PubMed         Abstract available

  20. PRATHIBHA S, White M, Kolbow M, Hui JYC, et al
    Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
    Breast Cancer Res Treat. 2024 Jan 28. doi: 10.1007/s10549-023-07203.
    PubMed         Abstract available

  21. NAAKTGEBOREN WR, Koevoets EW, Stuiver MM, van Harten WH, et al
    Effects of physical exercise during adjuvant chemotherapy for breast cancer on long-term tested and perceived cognition: results of a pragmatic follow-up study.
    Breast Cancer Res Treat. 2024 Jan 29. doi: 10.1007/s10549-023-07220.
    PubMed         Abstract available

  22. WOOD SJ, Gao Y, Lee JH, Chen J, et al
    High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy.
    Breast Cancer Res Treat. 2024 Jan 30. doi: 10.1007/s10549-023-07233.
    PubMed         Abstract available

  23. VERSCHOOR N, Bos MK, de Kruijff IE, Van MN, et al
    Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial.
    Breast Cancer Res Treat. 2024 Jan 31. doi: 10.1007/s10549-023-07231.
    PubMed         Abstract available

  24. ZHU E, Zhang L, Wang J, Hu C, et al
    Deep learning-guided adjuvant chemotherapy selection for elderly patients with breast cancer.
    Breast Cancer Res Treat. 2024 Jan 31. doi: 10.1007/s10549-023-07237.
    PubMed         Abstract available


    Cancer Lett

  25. CHEN SY, Zhang FL, Zhang YL, Liao L, et al
    Spermatid perinuclear RNA-binding protein promotes UBR5-mediated proteolysis of Dicer to accelerate triple-negative breast cancer progression.
    Cancer Lett. 2024 Jan 25:216672. doi: 10.1016/j.canlet.2024.216672.
    PubMed         Abstract available

  26. LIU C, Qian X, Yu C, Xia X, et al
    Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-alpha signaling axis in triple-negative breast cancer.
    Cancer Lett. 2024 Jan 24:216642. doi: 10.1016/j.canlet.2024.216642.
    PubMed         Abstract available


    Clin Breast Cancer

  27. NILSSON L, Khazaei S, Tryggvadottir H, Bjorner S, et al
    Pre- and Postoperative Antioxidant Use, Aryl Hydrocarbon Receptor (AhR) Activation and Clinical Outcome in Different Treatment Groups of Breast Cancer Patients.
    Clin Breast Cancer. 2023 Dec 21:S1526-8209(23)00306.
    PubMed         Abstract available

  28. MCKECHNIE T, Brown Z, Lovrics O, Yang S, et al
    Concurrent Use of Statins in Patients Undergoing Curative Intent Treatment for Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis.
    Clin Breast Cancer. 2023 Dec 16:S1526-8209(23)00305.
    PubMed         Abstract available

  29. HAN J, Hua H, Fei J, Liu J, et al
    Prediction of Disease-Free Survival in Breast Cancer using Deep Learning with Ultrasound and Mammography: A Multicenter Study.
    Clin Breast Cancer. 2024 Jan 17:S1526-8209(24)00006.
    PubMed         Abstract available


    Discov Oncol

  30. TURKOGLU F, Calisir A, Ozturk B
    Clinical importance of serum miRNA levels in breast cancer patients.
    Discov Oncol. 2024;15:19.
    PubMed         Abstract available

  31. LI W, Fu Y, Sun J, Gong H, et al
    Construction and in vitro evaluation of pH-sensitive nanoparticles to reverse drug resistance of breast cancer stem cells.
    Discov Oncol. 2024;15:21.
    PubMed         Abstract available

  32. SHEN WJ, Zhang Y
    RPN1 promotes the proliferation and invasion of breast cancer cells by activating the PI3K/AKT/mTOR signaling pathway.
    Discov Oncol. 2024;15:25.
    PubMed         Abstract available


    Int J Cancer

  33. RYBINSKA I, Mangano N, Romero-Cordoba SL, Regondi V, et al
    SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.
    Int J Cancer. 2024 Jan 30. doi: 10.1002/ijc.34859.
    PubMed         Abstract available


    J Clin Invest

  34. LI Z, Metzger Filho O, Viale G, dell'Orto P, et al
    HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial.
    J Clin Invest. 2024 Feb 1:e176454. doi: 10.1172/JCI176454.
    PubMed         Abstract available


    J Clin Oncol

  35. GANZ PA, Bandos H, Spanic T, Friedman S, et al
    Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
    J Clin Oncol. 2024 Feb 1:JCO2301214. doi: 10.1200/JCO.23.01214.
    PubMed         Abstract available


    J Natl Cancer Inst

  36. YANGUELA J, Jackson BE, Reeder-Hayes KE, Roberson ML, et al
    Simulating the population impact of interventions to reduce racial gaps in breast cancer treatment.
    J Natl Cancer Inst. 2024 Jan 27:djae019. doi: 10.1093.
    PubMed         Abstract available


    J Nucl Med

  37. JACENE H, Dietsche E, Specht J
    The Current and Future Roles of Precision Oncology in Advanced Breast Cancer.
    J Nucl Med. 2024 Feb 1:jnumed.122.264882. doi: 10.2967/jnumed.122.264882.
    PubMed         Abstract available


    Lancet Oncol

  38. MEATTINI I, Becherini C, Caini S, Coles CE, et al
    International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
    Lancet Oncol. 2024;25:e73-e83.
    PubMed         Abstract available


    NPJ Breast Cancer

  39. MEI J, Cai Y, Zhu H, Jiang Y, et al
    High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer.
    NPJ Breast Cancer. 2024;10:11.
    PubMed         Abstract available


    Oncogene

  40. SONG H, Zhao Z, Ma L, Zhao W, et al
    Novel exosomal circEGFR facilitates triple negative breast cancer autophagy via promoting TFEB nuclear trafficking and modulating miR-224-5p/ATG13/ULK1 feedback loop.
    Oncogene. 2024 Jan 27. doi: 10.1038/s41388-024-02950.
    PubMed         Abstract available

  41. GARIKAPATI K, Young IC, Hong S, Rai P, et al
    Blocking LBH expression causes replication stress and sensitizes triple-negative breast cancer cells to ATR inhibitor treatment.
    Oncogene. 2024 Jan 31. doi: 10.1038/s41388-024-02951.
    PubMed         Abstract available


    PLoS One

  42. SINKALA M, Naran K, Ramamurthy D, Mungra N, et al
    Machine learning and bioinformatic analyses link the cell surface receptor transcript levels to the drug response of breast cancer cells and drug off-target effects.
    PLoS One. 2024;19:e0296511.
    PubMed         Abstract available

  43. PIEDRA-DELGADO L, Chambergo-Michilot D, Morante Z, Fairen C, et al
    Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.
    PLoS One. 2024;19:e0293833.
    PubMed         Abstract available


    Radiol Imaging Cancer

  44. HAVER HL, Gupta AK, Ambinder EB, Bahl M, et al
    Evaluating the Use of ChatGPT to Accurately Simplify Patient-centered Information about Breast Cancer Prevention and Screening.
    Radiol Imaging Cancer. 2024;6:e230086.
    PubMed         Abstract available

  45. NGUYEN DL, Lotfalla M, Cimino-Mathews A, Habibi M, et al
    Radiologic-Pathologic Correlation of Nonmass Enhancement Contiguous with Malignant Index Breast Cancer Masses at Preoperative Breast MRI.
    Radiol Imaging Cancer. 2024;6:e230060.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.